Glivec case final hearing in India rescheduled for Sept
This article was originally published in Scrip
The Indian patent case concerning Novartis' anticancer, Glivec (imatinib mesylate), and its rejection due to a controversial provision in India's patent law, will now come up for hearing in the Supreme Court only in September.
You may also be interested in...
Years after a scathing Indian parliamentary report flagged concerns around regulatory lapses for drug approvals, an expert panel has endorsed the continued marketing of ambrisentan and everolimus in the country. But dronedarone, also featured in the report, is no longer sold by Sanofi in India.
Tecentriq cleared for extensive-stage small cell lung cancer in India but pricing remains a key constraining factor. Patient assistance schemes help but such novel therapies still unaffordable to a vast majority.